Don't Write Off This Lung Cancer Vaccine Just Yet

This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and biggest market movers. Market Checkup gives a full examination of a shocking medical device takeover, a hot biotech that can't find an acquirer, a surprise announcement bringing a failed drug, and a big deal in gene sequencing.

In this video, health-care analyst David Williamson discusses Oncothyreon's surprise 20% pop today. Its lung cancer vaccine Stimuvax, now under the name tecemotide, is back from its phase 3 trial failure last year. Oncothyreon's partner, the German pharma Merck KGaA, saw enough in a subgroup to start a new phase 3 trial. Watch and find out why, despite the seemingly good news, investors should be cautious about these developments.

Looking for more disruptive biotechs?
It's no secret that biotech stocks have been soaring recently, but the best investment strategy is to pick great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" not only shares stocks that could help you build long-term wealth, but also winning strategies that every investor should know. Click here to grab your free copy today.

The article Don't Write Off This Lung Cancer Vaccine Just Yet originally appeared on Fool.com.

David Williamson has no position in any stocks mentioned. Follow David on Twitter @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.